Increased Expression of P2RY2, CD248 and EphB1 in Gastric Cancers from Chilean Patients

Aquea, Gisela; Bresky, Gustavo; Lancellotti, Domingo; Madariaga, Juan Andrés; Zaffiri, Vittorio; Urzúa, Ulises; Häberle, Sergio; Bernal, Giuliano

doi:10.7314/apjcp.2014.15.5.1931

Cited by 26 publications

(18 citation statements)

References 28 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genes highly expressed in gastric cancer were CD248, NSDl, RABl7, ABCG8, Ephbl and P2RY2. P2RY2, Ephbl and CD248 were explored for gastric cancer detection [85]. The cross talk between tumor cells and the surrounding stroma contributes to hepatocellular carcinoma progression.…”

Section: Expression During Development and Pathologymentioning

confidence: 99%

CD248: A therapeutic target in cancer and fibrotic diseases

Teicher

2019

Oncotarget

View full text Add to dashboard Cite

CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells, by the pericyte component of tumor vasculature and by mesenchymal cells in some fibrotic diseases. CD248 is being targeted by several experimental therapeutics including antibodies, antibody drug conjugates, as an antigen for CART cells and in therapeutic vaccines. Although the function of CD248 has yet to be fully elucidated, this protein is a potential broad scope therapeutic target.

show abstract

Section: Expression During Development and Pathologymentioning

confidence: 99%

CD248: A therapeutic target in cancer and fibrotic diseases

Teicher

2019

Oncotarget

View full text Add to dashboard Cite

show abstract

“…These apparently discrepant observations may reflect the cancer cell-intrinsic functions of P2RX7, which is known to control proliferation and regulated cell death ( 145 ). Of note, increased P2RY2 mRNA levels have also been detected in gastric cancer biopsies from 14 patients (as compared to the adjacent healthy mucosa) ( 146 ), but these findings do not allow to determine whether gastric neoplasms were infiltrated by P2RY2 + immune cells or whether they overexpressed P2RY2.…”

Section: Extracellular Atp and Autophagymentioning

confidence: 99%

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

et al. 2015

View full text Add to dashboard Cite

It is now clear that human neoplasms form, progress, and respond to therapy in the context of an intimate crosstalk with the host immune system. In particular, accumulating evidence demonstrates that the efficacy of most, if not all, chemo- and radiotherapeutic agents commonly employed in the clinic critically depends on the (re)activation of tumor-targeting immune responses. One of the mechanisms whereby conventional chemotherapeutics, targeted anticancer agents, and radiotherapy can provoke a therapeutically relevant, adaptive immune response against malignant cells is commonly known as “immunogenic cell death.” Importantly, dying cancer cells are perceived as immunogenic only when they emit a set of immunostimulatory signals upon the activation of intracellular stress response pathways. The emission of these signals, which are generally referred to as “damage-associated molecular patterns” (DAMPs), may therefore predict whether patients will respond to chemotherapy or not, at least in some settings. Here, we review clinical data indicating that DAMPs and DAMP-associated stress responses might have prognostic or predictive value for cancer patients.

show abstract

“…It has been shown that P2Y2R is overexpressed in biopsies of basal cell and squamous cell carcinomas (non-melanoma skin cancers) [47]. One study also showed by cDNA microarray analysis that the P2RY2 transcript is highly expressed in fresh biopsies of gastric cancer tissue, compared to adjacent healthy tissue [48]. The incremented expression of P2Y2R was detected in primary cultured hepatocellular carcinoma cells and in the hepatocarcinoma-derived cell lines HepG2 and Bell-7404 compared with normal hepatocytes and the normal hepatocyte cell line LO2 [49].…”

Section: Purines In Proliferation and Tumor Growthmentioning

confidence: 99%

Purinergic Signaling in the Hallmarks of Cancer

Campos-Contreras

Dı́az-Muñoz

Vázquez‐Cuevas

2020

Cells

View full text Add to dashboard Cite

Cancer is a complex expression of an altered state of cellular differentiation associated with severe clinical repercussions. The effort to characterize this pathological entity to understand its underlying mechanisms and visualize potential therapeutic strategies has been constant. In this context, some cellular (enhanced duplication, immunological evasion), metabolic (aerobic glycolysis, failure in DNA repair mechanisms) and physiological (circadian disruption) parameters have been considered as cancer hallmarks. The list of these hallmarks has been growing in recent years, since it has been demonstrated that various physiological systems misfunction in well-characterized ways upon the onset and establishment of the carcinogenic process. This is the case with the purinergic system, a signaling pathway formed by nucleotides/nucleosides (mainly adenosine triphosphate (ATP), adenosine (ADO) and uridine triphosphate (UTP)) with their corresponding membrane receptors and defined transduction mechanisms. The dynamic equilibrium between ATP and ADO, which is accomplished by the presence and regulation of a set of ectonucleotidases, defines the pro-carcinogenic or anti-cancerous final outline in tumors and cancer cell lines. So far, the purinergic system has been recognized as a potential therapeutic target in cancerous and tumoral ailments.

show abstract

Increased Expression of P2RY2, CD248 and EphB1 in Gastric Cancers from Chilean Patients

Abstract: Background: Gastric cancer (GC) ranks as one of the major causes of mortality due to cancer worldwide. Materials and Methods: Using whole-genome a group of 14 GC cases. Results

Cited by 26 publications

References 28 publications

CD248: A therapeutic target in cancer and fibrotic diseases

CD248: A therapeutic target in cancer and fibrotic diseases

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

Purinergic Signaling in the Hallmarks of Cancer

Contact Info

Product

Resources

About